Alpha-7 nicotinic acetylcholine receptor (α7 nAChR) (α7 nAChR)

The alpha-7 nicotinic acetylcholine receptor (α7 nAChR) is a homopentameric ligand-gated ion channel primarily expressed in the central nervous system and on immune cells [3, 5, 9]. It is distinguished by its high permeability to calcium ions and rapid desensitization upon agonist binding [4, 8]. Biologically, it plays a critical role in modulating neurotransmitter release, enhancing synaptic plasticity, and regulating the cholinergic anti-inflammatory pathway by suppressing pro-inflammatory cytokine production [3, 14]. Dysfunction or reduced expression of α7 nAChRs is strongly linked to cognitive deficits in schizophrenia and Alzheimer's disease, as well as neuroinflammation in Parkinson's disease [1, 3, 8]. Pharmacological targeting involves the use of selective agonists and positive allosteric modulators (PAMs) to enhance cognitive function and provide neuroprotection [1, 4, 11]. However, clinical development has faced challenges regarding drug selectivity, particularly against the 5-HT3 receptor, and maintaining sustained efficacy due to the receptor's complex desensitization kinetics [1, 13]. Despite these hurdles, the receptor remains a high-priority target for treating neurodegenerative and neuropsychiatric conditions [4, 7].

Other names

CHRNA7Alpha7 nicotinic receptornAChR alpha7Homomeric alpha-7 nicotinic receptorNeuronal acetylcholine receptor subunit alpha-7

Agonism, partial agonism, and positive allosteric modulation (PAM) to enhance receptor activity and calcium signaling while managing rapid desensitization [1, 4, 8].